Bristol-Myers Squibb Co. (BMY) Stock News
Follow the latest Bristol-Myers Squibb Co. (BMY) news and market headlines alongside the live BMY price. Stay informed on what's moving BMY.
News
Read Full Article - Read Full Article
Bristol Myers Reports Preliminary Phase 3 Findings Of KarXT Treatment From 12-Week Open-Label Period Of ADEPT-1 Study And 52-Week OLE ADEPT-3 Study In Patients With Psychosis Associated With Alzheimer’s Disease
Preliminary findings from the ADEPT-1 12-week open-label lead-in period show observed improvements in hallucination and delusion scores from baselinePreliminary findings from the ADEPT-3 52-week open-label extension
Read Full Article - Read Full Article
Erasca Enters into Clinical Collaboration with Bristol Myers Squibb to Evaluate ERAS-0015 in Clinical Study with Navlimetostat
Erasca and Bristol Myers Squibb announced a clinical trial collaboration to evaluate Erasca's pan-RAS molecular glue ERAS-0015 in combination with BMS's PRMT5 inhibitor navlimetostat for MTAP-deleted pancreatic cancer. BMS will sponsor the Phase 1/2 trial while Erasca supplies ERAS-0015. The combination targets the dependency created by co-occurring RAS mutations in nearly all MTAP-deleted pancreatic cancers.
- Read Full Article
Biotechnology Market Companies 2027 Analysis: Amgen, Gilead, Regeneron, Vertex and Moderna Post Strong 2026 Results as Billion-Dollar Deals Reshape a Market Headed for USD 6.34 Trillion by 2035
The global biotechnology market, valued at USD 2.02 trillion in 2026, is projected to reach USD 6.34 trillion by 2035 at a 13.61% CAGR. Leading biotech companies including Amgen, Gilead, Regeneron, Vertex, and Moderna reported strong Q3 2026 results with revenue growth ranging from 8% to 36%. The sector experienced record dealmaking activity with major acquisitions totaling tens of billions of dollars, driven by patent expiries, strong cash flows, and strategic pipeline expansion in oncology, immunology, and advanced therapies.
- Read Full Article
Reported November 16, Roche Receives FDA Approval For Wiserdley In Combination With Everolimus For Breast Cancer Treatment
Wilserdly is the first and only next-generation all-oral SERD combination to significantly outperform standard endocrine combination in a post-CDK4/6 inhibitor setting in a head-to-head phase III trial (evERA)1In
- Read Full Article
5 Fantastic Dividend Stocks You May Be Overlooking
The article highlights five underrated dividend stocks offering attractive yields: Ares Capital (9.9% yield, 69 consecutive quarters of maintained/grown dividends), Bristol Myers Squibb (4% yield, 17 consecutive years of increases despite patent cliff concerns), Edison International (5.9% yield, 22 consecutive years of increases but facing wildfire litigation), MPLX LP (8.5% yield with 12.5% annual distribution growth), and NNN REIT (6% yield with 37 consecutive years of dividend increases, outperforming Realty Income).
- Read Full Article
5 Dividend Stocks With High Yields That Are Safer Than You Might Think
The article examines five high-yield dividend stocks that appear riskier than they actually are. Pfizer and Bristol Myers Squibb face normal pharmaceutical industry headwinds from patent expirations but maintain sustainable dividends through strong cash flows. REITs Realty Income and W.P. Carey are pressured by rising interest rates, but historical market adjustments should protect profitability. Hormel Foods, despite slow turnaround progress, has strong financials and backing from the Hormel Foundation, making its dividend safer than its yield suggests.
- Read Full Article
Bristol Myers Squibb's Growth Portfolio Now Brings In $7.7 Billion a Quarter. Here's Why That Changes the Stock's Story.
Bristol Myers Squibb faces upcoming patent expirations on older drugs, particularly Eliquis losing U.S. patent protection in 2028. However, the company's newer growth portfolio is already generating $7.7 billion quarterly in revenue, exceeding the $5.42 billion from legacy drugs. With a 4% dividend yield and reasonable 55% payout ratio, the stock may appeal to aggressive income investors despite near-term patent cliff risks.
- Read Full Article
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
The article compares Amgen and Vertex Pharmaceuticals as investment options for 2027. Amgen offers diversified revenue streams across multiple drug franchises with lower valuation metrics but faces biosimilar competition and pricing pressures. Vertex demonstrates faster growth driven by cystic fibrosis dominance and promising pipeline candidates like Povetacicept, though at a premium valuation. The analyst recommends Vertex for long-term growth investors despite higher valuations, citing its superior growth trajectory and innovative pipeline.
- Read Full Article
REPL Stock Up 80% in a Month on Tudriqev Launch & Pipeline Progress
Replimune's stock surged 80% over the past month following FDA accelerated approval and commercial launch of Tudriqev (RP1) in combination with Bristol Myers' Opdivo for treating unresectable advanced cutaneous melanoma. Early adoption at leading melanoma centers and better-than-expected Q2 2027 earnings results drove investor confidence. The company's pipeline candidate RP2 is advancing in multiple cancer indications with preliminary results expected in Q1 2027.
- Read Full Article
Bristol Myers Squibb Appoints Cristian Massacesi To Lead A Unified, End-To-End R&D Organization, Effective January 1, 2027
As part of this planned transition, Robert Plenge will remain with Bristol Myers Squibb in an advisory capacity through March 2027 to support a seamless transition before departing the company.Effective January 1, 2027,
Explore More US Stocks
Data Sources and Disclosures
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to BMY, including RealStocks and Stock Futures.
Disclaimer
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.
